Eli Lilly and Company has broken ground on a new $5-billion manufacturing facility in Goochland County, Virginia, west of Richmond, Virginia, which will produce active pharmaceutical ingredients (APIs ...
The deeper threat to the biopharmaceutical industry may come not from macro-level disruption, but from structural pressures ...
How AI and other digital tools are progressing across the bio/pharmaceutical industry is on top of mind. Key perspectives on ...
Merck KGaA has agreed to acquire Silence Therapeutics, a Cambridge, UK-based clinical-stage bio/pharmaceutical company developing short interfering RNA (siRNA) medicines, for $1.3 billion, ...
Sanofi has broken ground on a new insulin manufacturing facility in Frankfurt, Germany. The new facility will be built on a 36,000-square-meter footprint at the Sanofi BioCampus in Frankfurt.
The Board of Directors of CSL, a Melbourne, Australia-based bio/pharmaceutical company, has appointed Deborah Waterhouse, currently Chief Executive Officer (CEO) of ViiV Healthcare, a joint venture ...
Welcome to the newest Member Companies in the Drug, Chemical & Associated Technologies Association (DCAT). DCAT is pleased to welcome the following companies to the DCAT Member Community. To view all ...
Which CDMOs/CDMO are expanding manufacturing capacity for intermediates and small-molecule active pharmaceutical ingredients (APIs)? DCAT Value Chain Insights gives a roundup of recently announced, in ...
In looking at the news developments from the CDMO market in 2026, certain themes emerge. The blockbuster success of the glucagon-like peptide-1 (GLP-1) receptor agonists for treating obesity and Type ...
The global CMDO market for peptides and oligonucleotides (TIDES) is showing strong growth, fueled by new drug development, particularly for peptide-based drugs. The global CDMO market for peptides and ...
Novo Nordisk. Just this week (June 24, 2024), Novo Nordisk announced yet another multi-billion manufacturing expansion. The company plans to invest $4.1 billion to build a second fill–finish ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results